The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Asthenia

  • RESULTS: Sixteen patients received 77 courses at capecitabine doses from 950 to 1,500 mg/m(2)/d. The most common toxicities were hand-foot syndrome, diarrhea, nausea/vomiting, and asthenia [1].
  • The most frequently reported treatment-related adverse events with clentiazem were asthenia, headache (both 7.9%), first-degree atrioventricular block and dizziness (both 4.4%) [2].
  • Toxicities were mild to moderate and included asymptomatic, transient transaminasemia, fever, asthenia, hypoalbuminemia, nausea, vomiting, myalgias, rash, anorexia, vascular leak syndrome, and elevated creatinine kinase [3].
  • The most common adverse events with paroxetine were nausea, sexual dysfunction, somnolence, asthenia, headache, constipation, dizziness, sweating, tremor and decreased appetite [4].
  • The most common adverse events with zolmitriptan therapy are asthenia, heaviness other than that of the chest or neck, dry mouth, nausea, dizziness, somnolence, paraesthesia, warm sensation, tightness, vasodilation and chest pain [5].

Psychiatry related information on Asthenia


High impact information on Asthenia

  • Adverse reactions to riluzole included asthenia, spasticity, and mild elevations in aminotransferase levels [11].
  • More patients given LY334370 than placebo reported asthenia, somnolence, and dizziness [12].
  • Although the risk of fulminant hepatitis is very low, we recommend that, in patients taking pirprofen for more than 2 mo and complaining of asthenia, nausea, or vomiting, serum aminotransferase levels should be measured and administration of the drug should be interrupted as soon as an increased level is noted [13].
  • Raltitrexed doses of more than 3.0 mg/m(2) were not tolerated and were associated with dose-limiting asthenia, diarrhea, and AST/ALT elevation [14].
  • In approximately 5% of patients, amifostine therapy was interrupted due to cumulative asthenia, and in 10%, due to a fever/rash reaction [15].

Chemical compound and disease context of Asthenia

  • The most common adverse experiences attributed to terazosin monotherapy were dizziness and asthenia (9.7 percent and 6.6 percent, respectively) [16].
  • Side effect profiles of the two treatments were different, with nausea being the most commonly reported side effect during labetalol therapy, and asthenia, somnolence, and dry mouth during methyldopa therapy [17].
  • After L-carnitine treatment the blood and muscle levels of the metabolite increased simultaneously to reduced asthenia and cramps [18].
  • The most common adverse events associated with rizatriptan in recent randomised trials were asthenia/fatigue, dizziness, somnolence and nausea [19].
  • In early phase I/II trials, headache, gastrointestinal disturbances, rash, malaise, fatigue and/or asthenia were the most common adverse events reported with abacavir alone or in combination with other anti-HIV agents [20].

Biological context of Asthenia


Anatomical context of Asthenia


Gene context of Asthenia


  1. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. Nadella, P., Shapiro, C., Otterson, G.A., Hauger, M., Erdal, S., Kraut, E., Clinton, S., Shah, M., Stanek, M., Monk, P., Villalona-Calero, M.A. J. Clin. Oncol. (2002) [Pubmed]
  2. A dose-response study of clentiazem, a chloro-derivative of diltiazem, in patients with stable angina. CAMCAT Study Group. Waters, D., Garceau, D. J. Am. Coll. Cardiol. (1993) [Pubmed]
  3. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Frankel, A.E., Fleming, D.R., Hall, P.D., Powell, B.L., Black, J.H., Leftwich, C., Gartenhaus, R. Clin. Cancer Res. (2003) [Pubmed]
  4. Paroxetine: an update of its use in psychiatric disorders in adults. Wagstaff, A.J., Cheer, S.M., Matheson, A.J., Ormrod, D., Goa, K.L. Drugs (2002) [Pubmed]
  5. Zolmitriptan: a review of its use in migraine. Spencer, C.M., Gunasekara, N.S., Hills, C. Drugs (1999) [Pubmed]
  6. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. Beasley, C.M., Nilsson, M.E., Koke, S.C., Gonzales, J.S. The Journal of clinical psychiatry. (2000) [Pubmed]
  7. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Patterson, D., Abell, T., Rothstein, R., Koch, K., Barnett, J. Am. J. Gastroenterol. (1999) [Pubmed]
  8. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Dooley, M., Markham, A. Drugs & aging. (1998) [Pubmed]
  9. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Igual-Adell, R., Oltra-Alcaraz, C., Soler-Company, E., Sánchez-Sánchez, P., Matogo-Oyana, J., Rodríguez-Calabuig, D. Expert opinion on pharmacotherapy. (2004) [Pubmed]
  10. Pimozide in the treatment of some "social maladjustments" in "personality disorders". Collard, J. Acta psychiatrica Belgica. (1979) [Pubmed]
  11. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. Bensimon, G., Lacomblez, L., Meininger, V. N. Engl. J. Med. (1994) [Pubmed]
  12. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Goldstein, D.J., Roon, K.I., Offen, W.W., Ramadan, N.M., Phebus, L.A., Johnson, K.W., Schaus, J.M., Ferrari, M.D. Lancet (2001) [Pubmed]
  13. Pirprofen-induced fulminant hepatitis. Danan, G., Trunet, P., Bernuau, J., Degott, C., Babany, G., Pessayre, D., Rueff, B., Benhamou, J.P. Gastroenterology (1985) [Pubmed]
  14. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. Stevenson, J.P., Redlinger, M., Kluijtmans, L.A., Sun, W., Algazy, K., Giantonio, B., Haller, D.G., Hardy, C., Whitehead, A.S., O'Dwyer, P.J. J. Clin. Oncol. (2001) [Pubmed]
  15. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. Koukourakis, M.I., Kyrias, G., Kakolyris, S., Kouroussis, C., Frangiadaki, C., Giatromanolaki, A., Retalis, G., Georgoulias, V. J. Clin. Oncol. (2000) [Pubmed]
  16. Long-term experience with terazosin for treatment of mild to moderate hypertension. Mersey, J.H. Am. J. Med. (1986) [Pubmed]
  17. Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. Wallin, J.D., Wilson, D., Winer, N., Maronde, R.F., Michelson, E.L., Langford, H., Maloy, J., Poland, M. Am. J. Med. (1983) [Pubmed]
  18. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Bellinghieri, G., Savica, V., Mallamace, A., Di Stefano, C., Consolo, F., Spagnoli, L.G., Villaschi, S., Palmieri, G., Corsi, M., Maccari, F. Am. J. Clin. Nutr. (1983) [Pubmed]
  19. Rizatriptan: an update of its use in the management of migraine. Wellington, K., Plosker, G.L. Drugs (2002) [Pubmed]
  20. Abacavir. Foster, R.H., Faulds, D. Drugs (1998) [Pubmed]
  21. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Kosmas, C., Tsavaris, N.B., Polyzos, A., Malamos, N.A., Katsikas, M., Antonopoulos, M.J. Br. J. Cancer (2000) [Pubmed]
  22. Androgens and aging in men. Swerdloff, R.S., Wang, C. Exp. Gerontol. (1993) [Pubmed]
  23. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension. Salvadeo, A., Villa, G., Segagni, S., Piazza, V., Picardi, L., Romano, M., Parini, J. Arzneimittel-Forschung. (1985) [Pubmed]
  24. Carnitine and hemodialysis. Bellinghieri, G., Santoro, D., Calvani, M., Mallamace, A., Savica, V. Am. J. Kidney Dis. (2003) [Pubmed]
  25. Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels. Mohammadi, B., Lang, N., Dengler, R., Bufler, J. Muscle Nerve (2002) [Pubmed]
  26. Pharmacologic and therapeutic features of sulbutiamine. Van Reeth, O. Drugs of today (Barcelona, Spain : 1998) (1999) [Pubmed]
  27. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. Moises, H.W., Zoega, T., Gottesman, I.I. BMC psychiatry [electronic resource]. (2002) [Pubmed]
  28. When and how should we screen for hereditary hemochromatosis? Chalès, G., Guggenbuhl, P. Joint, bone, spine : revue du rhumatisme. (2003) [Pubmed]
  29. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer. Lissoni, P., Barni, S., Tisi, E., Rovelli, F., Pittalis, S., Rescaldani, R., Vigoré, L., Biondi, A., Ardizzoia, A., Tancini, G. Eur. J. Cancer (1993) [Pubmed]
  30. Interferon in metastatic renal cell carcinoma. Fosså, S.D. Semin. Oncol. (2000) [Pubmed]
  31. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Correale, P., Marsili, S., Sabatino, M., Montagnani, F., Giorgi, G., Francini, G. Oncol. Rep. (2005) [Pubmed]
  32. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., Baly, D., Baughman, S.A., Twaddell, T., Glaspy, J.A., Slamon, D.J. J. Clin. Oncol. (1998) [Pubmed]
WikiGenes - Universities